The first results using mesothelin-directed CAR T cells (CARTmeso cells) were reported by Beatty et al. in a case report from two patients, one with malignant pleural mesothelioma (MPM) and a second with pancreatic cancer (55). This evidence concerns the gene MSLN and pancreatic neoplasm.